OptiNose (OPTN) Expected to Announce Earnings on Thursday

Posted by Tech Dows on Mar 19th, 2025

OptiNose (NASDAQ:OPTN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect OptiNose to post earnings of ($0.67) per share and revenue of $21.02 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

OptiNose Stock Performance

Shares of OptiNose stock opened at $5.80 on Wednesday. OptiNose has a twelve month low of $4.82 and a twelve month high of $29.65. The firm has a market cap of $58.35 million, a P/E ratio of -1.38 and a beta of -0.30. The firm’s 50-day simple moving average is $5.80 and its 200-day simple moving average is $8.23.

Insider Buying and Selling

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the transaction, the chief executive officer now owns 126,931 shares in the company, valued at approximately $671,464.99. The trade was a 4.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on OPTN. HC Wainwright lifted their price objective on OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Lake Street Capital decreased their price target on OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th.

View Our Latest Stock Analysis on OPTN

OptiNose Company Profile

(Get Free Report)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.